SNY - Sanofi

NYSE - NYSE Delayed Price. Currency in USD
43.20
-1.40 (-3.14%)
At close: 4:01PM EST

43.26 +0.06 (0.14%)
After hours: 4:49PM EST

Stock chart is not supported by your current browser
Previous Close44.60
Open42.84
Bid0.00 x 0
Ask0.00 x 0
Day's Range42.69 - 43.35
52 Week Range39.42 - 50.65
Volume8,594,041
Avg. Volume1,328,239
Market Cap108.128B
Beta0.75
PE Ratio (TTM)9.89
EPS (TTM)4.37
Earnings DateN/A
Forward Dividend & Yield1.64 (3.68%)
Ex-Dividend Date2017-05-11
1y Target Est49.50
Trade prices are not sourced from all markets
  • Merger Monday for biotech
    CNBC Videos12 hours ago

    Merger Monday for biotech

    CNBC's Meg Tirrell reports on two major deals in the biotech space: Sanofi buying Bioverativ and Celgene buying Juno Therapeutics.

  • Big pharma on a buying spree as Celgene buys Juno and San...
    CNBC Videos14 hours ago

    Big pharma on a buying spree as Celgene buys Juno and San...

    The "Squawk on the Street" crew discusses Celgene's $9 billion cash deal for Juno Therapeutics and Sanofi's $11.6 billion bid for Massachusetts-based Bioverativ.

  • Asian shares rise on global growth hopes, US shutdown's end
    Associated Press35 minutes ago

    Asian shares rise on global growth hopes, US shutdown's end

    HONG KONG (AP) — Asian stock markets posted strong gains on Tuesday, as an upbeat forecast for global economic growth and the end of the U.S. government shutdown helped lift sentiment.

  • The Wall Street Journal2 hours ago

    [$$] High Prices Won’t Deter Biotech Deals

    Expect more expensive biotech acquisitions after two high-priced deals were announced Monday.

  • The Wall Street Journal2 hours ago

    [$$] Big Drugmakers Pay Big Prices for Promising Biotechs

    Celgene and Sanofi are the latest big drugmakers willing to pay heft premiums for acquisitions amid an increasingly scarce roster of companies with promising products.

  • 3 Stocks for Warren Buffett Fans
    Motley Fool2 hours ago

    3 Stocks for Warren Buffett Fans

    If you like the Oracle of Omaha, you'll love these three companies.

  • Why 2017 Was a Year to Forget for Regeneron Pharmaceuticals, Inc.
    Motley Fool3 hours ago

    Why 2017 Was a Year to Forget for Regeneron Pharmaceuticals, Inc.

    Find out why shareholders had to endure a roller-coaster ride to nowhere.

  • What Happened in the Stock Market Today
    Motley Fool6 hours ago

    What Happened in the Stock Market Today

    On a record day for the market, Halliburton reported a strong quarter and Sanofi is buying Bioverativ in a big biotech deal.

  • Will Biotech's Merger 'Spigot' Turn On After Juno, Bioverativ?
    Investor's Business Daily7 hours ago

    Will Biotech's Merger 'Spigot' Turn On After Juno, Bioverativ?

    Celgene will buy Juno Therapeutics for $9 billion and French pharma Sanofi will pay $11.6 billion for Bioverativ.

  • Celgene Will Buy Juno Therapeutics For $9 Billion; Sanofi Acquires Bioverativ
    Investor's Business Daily7 hours ago

    Celgene Will Buy Juno Therapeutics For $9 Billion; Sanofi Acquires Bioverativ

    Celgene will acquire Juno Therapeutics for $9 billion. Sanofi reached a deal Monday to buy hemophilia drugmaker Bioverativ for $11.6 billion, or $105 a share.

  • TheStreet.com7 hours ago

    Dow, S&P 500 and Nasdaq Post New Records as Senate Reaches Deal to End Shutdown

    Stocks hit fresh records on Monday after a deal is reached to end the three-day government shutdown.

  • InvestorPlace11 hours ago

    Is Sanofi’s Bioverative Inc Buyout Just the Start?

    Bioverativ Inc (NASDAQ:BIVV), spun out of Biogen Inc. (NASDAQ:BIIB) less than a year ago, drew an $11.6 billion bid from Sanofi SA (ADR) (NYSE:SNY) on Jan. 22, a 64% premium over its closing price on Jan. 19. The bid, $105 per share, could be just the start of a shopping bonanza as big pharma companies seek to grow their drug pipelines through acquisitions of smaller biotech companies.

  • Behind Novartis’s 4Q17 Estimates: Innovative Medicines
    Market Realist12 hours ago

    Behind Novartis’s 4Q17 Estimates: Innovative Medicines

    Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products. The segment’s contribution is ~67% of NVS’s total revenues.

  • Reuters12 hours ago

    Biotech M&A takes off as Sanofi and Celgene spend $20 billion

    The acquisitions will fuel expectations for a busy year of mergers and acquisitions (M&A) as large drugmakers snap up promising assets from smaller rivals to help revive growth. Sanofi agreed to buy U.S. haemophilia expert Bioverativ for $11.6 billion, its biggest deal for seven years, while Celgene is paying about $9 billion for the 90 percent of cancer specialist Juno Therapeutics it does not already own.

  • Reuters12 hours ago

    Biotech M&A takes off as Sanofi and Celgene spend $20 billion

    The acquisitions will fuel expectations for a busy year of mergers and acquisitions (M&A) as large drugmakers snap up promising assets from smaller rivals to help revive growth. Sanofi agreed to buy U.S. hemophilia expert Bioverativ for $11.6 billion, its biggest deal for seven years, while Celgene is paying about $9 billion for the 90 percent of cancer specialist Juno Therapeutics it does not already own.

  • Reuters12 hours ago

    New drugs recast $10 billion haemophilia market as Sanofi swoops in

    Sanofi is placing a big bet on the $10 billion-a-year haemophilia market at a testing time, as scientific advances overhaul traditional approaches to treating the rare uncontrolled bleeding disorder. The French drugmaker's decision to buy U.S. haemophilia specialist Bioverativ for $11.6 billion exposes it to competition from Roche's new drug Hemlibra and looming threats from gene therapy. It also offers a potential launchpad for Sanofi's own experimental medicine fitusiran.

  • Reuters12 hours ago

    Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion

    French healthcare group Sanofi (SASY.PA) has agreed to buy U.S. haemophilia specialist Bioverativ (BIVV.O) for $11.6 billion(8.34 billion pounds), its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases. Several analysts said the deal looked expensive, given uncertainties in the haemophilia market due to the arrival of new drug treatments, and Sanofi shares fell 4 percent on Monday, the worst performance on France's benchmark CAC-40 index. The move comes at a time of renewed interest by large drugmakers in smaller biotech firms, with Celgene (CELG.O) also announcing a $9 billion deal to buy Juno Therapeutics (JUNO.O), and predictions by some experts that 2018 will see a substantial pick-up in mergers and acquisitions.

  • Health-Care Deals Fire Up With Drug Giants Facing Price Pressure
    Bloomberg12 hours ago

    Health-Care Deals Fire Up With Drug Giants Facing Price Pressure

    The new year’s health-care deals began to snowball as Sanofi and Celgene Corp. scooped up assets that promise to offset pricing pressure for some of their top-selling drugs.

  • Biotech's $20 Billion Merger Monday Results May Disappoint
    Bloomberg13 hours ago

    Biotech's $20 Billion Merger Monday Results May Disappoint

    Both Celgene and Sanofi seem to have been pressured into iffy deals.

  • TheStreet.com13 hours ago

    Dow, S&P 500 and Nasdaq Shake Off Government Shutdown to Trade Higher

    Stocks turn higher on Monday, as investors watch for the impact of a federal government shutdown that entered its third day.

  • Sanofi to Acquire Haemophilia Focused Bioverativ, Stock Dips
    Zacks14 hours ago

    Sanofi to Acquire Haemophilia Focused Bioverativ, Stock Dips

    Sanofi (SNY) is set to acquire blood disorder focused biopharmaceutical company, Bioverativ, for $11.6 billion.

  • PR Newswire14 hours ago

    Johnson Fistel, Announces Investigations of the Proposed Sales of Bioverativ Inc., and Juno Therapeutics, Inc.

    Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Bioverativ Inc. (BIVV) ("Bioverativ ") breached their fiduciary duties in connection with the proposed sale of the Company to Sanofi (SNY). On January 22, 2018, Bioverativ announced that it had signed a definitive merger agreement with Sanofi.

  • Inside Novartis’s 4Q17 Earnings: Analyst Estimates
    Market Realist15 hours ago

    Inside Novartis’s 4Q17 Earnings: Analyst Estimates

    Novartis’s 4Q17 Earnings: Behind the ExpectationsA look at Novartis’s earnings

  • Why Bioverativ Inc. Stock Is Soaring Today
    Motley Fool15 hours ago

    Why Bioverativ Inc. Stock Is Soaring Today

    Sanofi made its first major acquisition in nearly seven years by buying the hemophilia specialist Bioverativ.

  • Associated Press16 hours ago

    France's Sanofi buys US hemophilia specialist Bioverativ

    PARIS (AP) — France-based drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases.